This content has been archived. It may no longer be relevant
Published by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Pharmaceutical Research and Manufacturers of America (PhRMA)
The COVID-19 pandemic has led to new ways of working for biopharmaceutical companies, which have replaced in-office visits and face-to-face congresses with virtual engagements to maintain dialogue and scientific exchange with the medical community while protecting the health and safety of patients, healthcare professionals, and their own employees. Even as economies open, it is anticipated that virtual meetings and congresses will continue. The IFPMA’s Ethos and Code of Practice set global standards for industry business practices, which must be maintained in the virtual setting. In response to Company and Association questions, IFPMA, EFPIA, and PhRMA are issuing this guidance on Virtual International Medical Congresses impacted by COVID-19, which will be in effect until December 31, 2020. This provisional guidance may be amended to take into consideration experience in the coming weeks/months. Companies should adhere to the requirements established by their country’s applicable laws, regulations, or industry codes of practice. In the event of a conflict between the provisions of the applicable laws, regulations, and codes, the more restrictive of the conflicting provisions should apply.
To review the Guidelines go to https://www.ifpma.org/wp-content/uploads/2020/07/COVID_eBIC-guidance_Virtual-International-Congresses.pdf